Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

A ground breaking study mapping the immune microenvironment in Multiple Myeloma identifies critical immune changes and ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing ...

Assessing patient fitness involves more than evaluating chronological age, noted Brandon Blue, MD, of the Moffitt Cancer ...

Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Researchers sought to better understand the experiences of patients living with multiple myeloma and their perceptions of palliative care.

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...